Leeds Institute of Molecular Medicine, University of Leeds, Leeds LS9 7TF, UK.
Breast Cancer Res. 2011 Aug 12;13(4):215. doi: 10.1186/bcr2889.
Breast cancer is a complex and heterogeneous disease. Gene expression profiling has contributed significantly to our understanding of this heterogeneity at a molecular level, refining taxonomy based on simple measures such as histological type, tumour grade, lymph node status and the presence of predictive markers like oestrogen receptor and human epidermal growth factor receptor 2 (HER2) to a more sophisticated classification comprising luminal A, luminal B, basal-like, HER2-positive and normal subgroups. In the laboratory, breast cancer is often modelled using established cell lines. In the present review we discuss some of the issues surrounding the use of breast cancer cell lines as experimental models, in light of these revised clinical classifications, and put forward suggestions for improving their use in translational breast cancer research.
乳腺癌是一种复杂且异质性的疾病。基因表达谱分析在分子水平上极大地促进了我们对这种异质性的理解,它对基于组织学类型、肿瘤分级、淋巴结状态和预测标志物(如雌激素受体和人表皮生长因子受体 2 (HER2))等简单指标的分类进行了精细化,形成了更复杂的分类,包括 luminal A、luminal B、基底样、HER2 阳性和正常亚组。在实验室中,乳腺癌通常使用已建立的细胞系进行建模。在本综述中,我们根据这些修订的临床分类,讨论了使用乳腺癌细胞系作为实验模型时的一些问题,并提出了改进它们在转化乳腺癌研究中应用的建议。